19.97USD-2.06%Mkt Cap: 702.23M USDP/E: —Last update: 2026-06-01
Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's product pipeline includes ALTO-100, which is in Phase 2b clinical trial for the treatment of patients wit…
Industry Peers
Biotechnology111.39BUSDP/E 26.0
100.62BDKKP/E 19.4
62.97BUSDP/E 14.7
48.39BEURP/E 31.7
44.65BEURP/E 37.2
40.10BUSDP/E 75.3
35.22BUSD—
32.91BSEKP/E 48.6
Indicators:|
Key Statistics
Company
Market Cap702.23M USD
Enterprise Value462.48M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-63.24M USD
Revenue/Share—
Last Price19.97 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees68
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-5.85
PEG—
EV/EBITDA-5.99
EV/Revenue—
P/S—
P/B2.89
EPS (TTM)-2.43
EPS (Forward)-3.43
52W Range
2.15068% of range28.44
52W High28.44 USD
52W Low2.150 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-41.84%
ROA-34.24%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-51.77M USD
CapEx (TTM)24.00K USD
FCF Margin—
FCF Yield-5.69%
Net Debt-241.85M USD
Net Debt/EBITDA3.13
Balance Sheet
Debt/Equity0.16
Current Ratio20.52
Quick Ratio20.11
Book Value/Sh6.943 USD
Cash/Share7.516 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.2 (Strong Buy)
Target (Mean)35.13 USD
Target Range24.00 USD – 50.00 USD
# Analysts11
Ownership
Shares Out.35.09M
Float23.95M
Insiders4.55%
Institutions82.05%
Short Interest
Short Ratio5.3d
Short % Float5.49%
Short % Out.4.59%
Shares Short1.61M
Short (prev mo.)2.19M
Technical
SMA 5023.17 (-13.8%)
SMA 20015.17 (+31.6%)
Beta—
S&P 52W Chg27.70%
Avg Vol (30d)277.48K
Avg Vol (10d)312.85K
Technical Indicators
RSI (14)37.2
MACD-0.9538
MACD Signal-0.6327
MACD Hist.-0.3212
BB Upper26.46 USD
BB Middle22.77 USD
BB Lower19.08 USD
BB Width32.40%
ATR (14)1.547 USD
Vol Ratio (20d)0.26x